|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/14/21 Electromedical Technologies, Inc. 10-Q 3/31/21 55:4.4M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 329K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 20K
3: EX-32.1 Certification -- §906 - SOA'02 HTML 18K
10: R1 Document and Entity Information HTML 47K
11: R2 Balance Sheets HTML 104K
12: R3 Balance Sheets (Parenthetical) HTML 29K
13: R4 Statements of Operations HTML 59K
14: R5 Statement of Changes in Stockholders' Deficit HTML 62K
15: R6 Statements of Cash Flows HTML 98K
16: R7 Organization and Nature of Business HTML 20K
17: R8 Summary of Significant Accounting Policies HTML 116K
18: R9 Property and Equipment HTML 38K
19: R10 Notes Payable HTML 67K
20: R11 Long-Term Debt HTML 23K
21: R12 Derivative Liabilities HTML 46K
22: R13 Related Party Transactions HTML 21K
23: R14 Stockholders' Deficit HTML 23K
24: R15 Stock Options and Warrants HTML 118K
25: R16 Commitments and Contingencies HTML 21K
26: R17 Subsequent Events HTML 21K
27: R18 Summary of Significant Accounting Policies HTML 138K
(Policies)
28: R19 Summary of Significant Accounting Policies HTML 95K
(Tables)
29: R20 Property and Equipment (Tables) HTML 36K
30: R21 Notes Payable (Tables) HTML 43K
31: R22 Derivative Liabilities (Tables) HTML 46K
32: R23 Stock Options and Warrants (Tables) HTML 129K
33: R24 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Going HTML 25K
Concern (Details)
34: R25 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 28K
Revenue Recognition (Details)
35: R26 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 40K
Financial Instruments and Concentrations of
Business and Credit Risk (Details)
36: R27 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 34K
Disclosure of Fair Value (Details)
37: R28 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 27K
Changes in Level 3 liabilities measured at fair
value on a recurring basis (Details)
38: R29 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 21K
Additional information (Details)
39: R30 PROPERTY AND EQUIPMENT - Summery of Property and HTML 29K
Equipment (Details)
40: R31 PROPERTY AND EQUIPMENT - Additional Information HTML 19K
(Details)
41: R32 NOTES PAYABLE - Convertible Note (Details) HTML 25K
42: R33 NOTES PAYABLE - Assumptions used in the HTML 29K
determination of the fair value of the warrant
(Details)
43: R34 NOTES PAYABLE - Additional Information (Details) HTML 288K
44: R35 LONG-TERM DEBT - Additional Information (Details) HTML 62K
45: R36 DERIVATIVE LIABILITIES - Fair value of derivative HTML 25K
liability (Details)
46: R37 DERIVATIVE LIABILITIES - Black Scholes (Details) HTML 30K
47: R38 Related Party Transactions (Details) HTML 29K
48: R39 STOCKHOLDERS' DEFICIT - Additional Information HTML 53K
(Details)
49: R40 STOCK OPTIONS AND WARRANTS - Stock options HTML 63K
activity (Details)
50: R41 STOCK OPTIONS AND WARRANTS - Fair value of the HTML 66K
warrant awarded (Details)
51: R42 STOCK OPTIONS AND WARRANTS - Additional HTML 46K
Information (Details)
52: R43 Subsequent Events (Details) HTML 32K
54: XML IDEA XML File -- Filing Summary XML 97K
53: EXCEL IDEA Workbook of Financial Reports XLSX 68K
4: EX-101.INS XBRL Instance -- elcq-20210331 XML 1.23M
6: EX-101.CAL XBRL Calculations -- elcq-20210331_cal XML 102K
7: EX-101.DEF XBRL Definitions -- elcq-20210331_def XML 363K
8: EX-101.LAB XBRL Labels -- elcq-20210331_lab XML 960K
9: EX-101.PRE XBRL Presentations -- elcq-20210331_pre XML 670K
5: EX-101.SCH XBRL Schema -- elcq-20210331 XSD 135K
55: ZIP XBRL Zipped Folder -- 0001104659-21-066713-xbrl Zip 109K
EXHIBIT 31.1
CERTIFICATION OF CHIEF EXECUTIVE & CHIEF FINANCIAL OFFICER
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, I, Matthew Wolfson, certify that:
1. I have reviewed this report on Form 10-Q of Electromedical Technologies, Inc., for the fiscal quarter ended March 31, 2021;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonable likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.
Date: May 14, 2021
| By: | /s/ Matthew Wolfson | |
| Matthew Wolfson | ||
| President & Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| Chief Financial Officer | ||
| (Principal Financial and Accounting Officer) | ||
C:
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/14/21 | 4 | ||
| For Period end: | 3/31/21 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/14/22 Electromedical Technologies, Inc. S-1/A 5:1.8M Toppan Merrill/FA 1/07/22 Electromedical Technologies, Inc. S-1/A 1/06/22 5:1.8M Toppan Merrill/FA 12/21/21 Electromedical Technologies, Inc. S-1 5:2.3M Toppan Merrill/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/30/21 Electromedical Technologies, Inc. 10-K 12/31/20 81:7.8M Toppan Merrill/FA 2/12/21 Electromedical Technologies, Inc. 8-K:1,2,3,9 2/08/21 5:571K Toppan Merrill/FA 8/05/20 Electromedical Technologies, Inc. 8-A12G 5:314K Toppan Merrill/FA 7/20/20 Electromedical Technologies, Inc. S-1/A 47:27M Toppan Merrill/FA |